3 Stocks to Watch For: E*TRADE Financial Corporation (ETFC), MannKind Corporation (MNKD), Sarepta Therapeutics, Inc. (SRPT)

E*TRADE Financial Corporation (ETFC) saw its value increase by 1.69% as the stock gained $0.6 to finish the day at a closing price of $36.16. The stock was higher in trading and has fluctuated between $20.31-$38.61 per share for the past year. The shares, which traded within a range of $35.81 to $36.49 during the day, are up by 14.5% in the past three months and up by 43.38% over the past six months. It is currently trading -0.36% below its 20 day moving average and 1.07% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $42.82 a share over the next twelve months. The current relative strength index (RSI) reading is 51.31.The technical indicator lead us to believe there will be no major movement any time soon, hold.

E*TRADE Financial Corporation, a financial services company, provides brokerage and related products and services primarily to individual retail investors under the E*TRADE Financial brand name. It operates through two segments, Trading and Investing, and Balance Sheet Management. The Trading and Investing segment offers retail brokerage products and services, investor-focused banking products, and corporate services. The Balance Sheet Management segment manages asset allocation; loans previously originated by the company or purchased from third parties; deposits and customer payables; and credit, liquidity, and interest rate risk. The company provides its services to customers through digital platforms; and a network of customer service representatives and financial consultants through phone, email, and online at two branches, as well as in person through 30 branches across the United States. E*TRADE Financial Corporation was incorporated in 1982 and is headquartered in New York, New York.

MannKind Corporation (MNKD) shares were up in last trading by 8.14% to $0.56. It experienced lighter than average volume on day. The stock increased in value by almost 4.05% over the past week and fell -12.86% in the past month. It is currently trading -11.41% below its 50 day moving average and -29.52% below its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -74.87% decrease in value from its one year high of $2.24. The RSI indicator value of 43.77, lead us to believe that it is a hold for now.

MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes patients in the United States. Its approved product is AFREZZA, a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. MannKind Corporation has license and collaboration agreement with Sanofi-Aventis Deutschland GmbH for the development of AFREZZA. The company was founded in 1991 and is headquartered in Valencia, California.

Sarepta Therapeutics, Inc. (SRPT) traded within a range of $26.26 to $27.85 after opening the day at $27.81. The company has seen its stock increase in value by 0.87% so far this year. The stock was down close to -0.57% on active volume in last trading session and closed at $27.67 per share. After the recent fall, the stock is currently holding -56.58% below its 52 week high of $63.73 and 245.88% above its 12-month low of $8. The shares are down by over -32.51% in the last three months, and the RSI indicator value of 37.5 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. The company’s lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development for the treatment of individuals with Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease caused by the absence of dystrophin. It is also developing exon-skipping drugs for the treatment of DMD; and therapeutic candidates for the treatment of infectious diseases, such as influenza, Marburg, and Ebola. The company has a strategic alliance with Charley’s Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies; a license agreement with the University of Western Australia for the use of antisense sequences in the treatment of DMD; and a research collaboration agreement with Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD. It also has a research and option agreement with Nationwide Children’s Hospital for microdystrophin gene therapy program. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

 

Stocks To Track: Community Health Systems, Inc. (CYH), Sarepta Therapeutics, Inc. (SRPT), Gannett Co., Inc. (GCI)

Community Health Systems, Inc. (CYH) fell -2.09% during last trading as the stock lost $-0.14 to finish the day at $6.56 with about 2.08M shares changing hands, compared to its three month average trading volume of 3.43M. The $761.68M market cap company, which fluctuated between $6.54 and $6.83 during the day, currently situated 58.07% above its 52 week low of $4.15 and -69.32% away from its one year high of $21.38. The RSI of 53.58 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Community Health Systems, Inc., together with its subsidiaries, owns, leases, and operates general acute care hospitals in the United States. It offers general acute care, emergency room, general and specialty surgery, critical care, internal medicine, obstetrics, diagnostic, psychiatric, and rehabilitation services, as well as skilled nursing and home care services. The company also provides outpatient services at urgent care centers, occupational medicine clinics, imaging centers, cancer centers, ambulatory surgery centers, and home health and hospice agencies. In addition, it offers management and consulting services to non-affiliated general acute care hospitals. As of February 15, 2016, the company owned, leased, or operated 195 affiliated hospitals in 29 states with approximately 30,000 licensed beds. Community Health Systems, Inc. was founded in 1985 and is headquartered in Franklin, Tennessee.

Sarepta Therapeutics, Inc. (SRPT) dropped $-1.51 to close the day at a new closing price of $27.83, a -5.15% decrease in value from its previous closing price that moved the stock 247.87% above its 52 week low of $8. A total of 2.04M shares exchanged hands during the day compared with its three month average trading volume of 2.44M. The stock, which fluctuated between $27.83 and $29.44 during the day, currently situated -56.33% below its 52 week high. The stock is down by -21.72% in the past one month and down by -34.78% over the past three months. With a one year target estimate of $62.89 and RSI of 38.16, the stock still has upside potential, making it a hold for now.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. The company’s lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development for the treatment of individuals with Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease caused by the absence of dystrophin. It is also developing exon-skipping drugs for the treatment of DMD; and therapeutic candidates for the treatment of infectious diseases, such as influenza, Marburg, and Ebola. The company has a strategic alliance with Charley’s Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies; a license agreement with the University of Western Australia for the use of antisense sequences in the treatment of DMD; and a research collaboration agreement with Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD. It also has a research and option agreement with Nationwide Children’s Hospital for microdystrophin gene therapy program. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

Gannett Co., Inc. (GCI) had a active trading with around 2.04M shares changing hands compared to its three month average trading volume of 1.06M. The stock traded between $8.84 and $9.14 before closing at the price of $8.94 with -1.22% change on the day. The McClean Virginia 22107 based company is currently trading 24.55% above its 52 week low of $7.3 and -47.45% below its 52 week high of $17.72. Both the RSI indicator and target price of 36.83 and $11 respectively, lead us to believe that it should be put on hold over the coming weeks.

Gannett Co., Inc. operates as a multi-platform news and information company. The company’s operations comprise USA TODAY, a newspaper in print and digital circulation; 92 daily local publications in the United States and Guam; approximately 400 non-daily publications in the United States; and approximately 150 local news brands online, mobile, and in print in the United Kingdom. It also provides commercial printing, marketing, and data services. The company was formerly known as Gannett SpinCo, Inc. and changed its name to Gannett Co., Inc. in May 2015. Gannett Co., Inc. was incorporated in 2014 and is based in McLean, Virginia.

 

Stocks In Action: Bonanza Creek Energy Inc. (BCEI), Sarepta Therapeutics, Inc. (SRPT), PBF Energy Inc. (PBF)

Bonanza Creek Energy Inc. (BCEI) traded within a range of $2.05 to $2.23 after opening the day at $2.08. The company has seen its stock increase in value by 103.92% so far this year. The stock was down close to 0% on light volume in last trading session and closed at $2.08 per share. After the recent fall, the stock is currently holding -55.46% below its 52 week high of $4.67 and 246.67% above its 12-month low of $0.6. The shares are up by over 136.36% in the last three months, and the RSI indicator value of 47.9 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Bonanza Creek Energy Inc., an independent energy company, engages in the acquisition, exploration, development, and production of onshore oil and associated liquids-rich natural gas in the United States. The company’s oil and liquids weighted assets are located primarily in the Wattenberg Field in Colorado; and the Dorcheat Macedonia Field in southern Arkansas. It also owns and operates oil-producing assets in the North Park Basin in Colorado; and the McKamie Patton Field in Southern Arkansas. Bonanza Creek Energy Inc. was founded in 2010 and is headquartered in Denver, Colorado. On January 4, 2017, Bonanza Creek Energy Inc. along with its affiliates filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Sarepta Therapeutics, Inc. (SRPT) continued its upward trend with the stock climbing 0.27% or $0.08 to close the day at $29.34 on light trading volume of 2.08M shares, compared to its three month average trading volume of 2.47M. The Cambridge Massachusetts 02142 based company has been outperforming the biotechnology group over the past 52 weeks, with the stock gaining 159.88%, compared to the industry which has advanced 7.38% over the same period. With RSI of 42.88, the stock should still continue to rise and get closer to its one year target estimate of $62.89, making it a hold for now.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. The company’s lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development for the treatment of individuals with Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease caused by the absence of dystrophin. It is also developing exon-skipping drugs for the treatment of DMD; and therapeutic candidates for the treatment of infectious diseases, such as influenza, Marburg, and Ebola. The company has a strategic alliance with Charley’s Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies; a license agreement with the University of Western Australia for the use of antisense sequences in the treatment of DMD; and a research collaboration agreement with Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD. It also has a research and option agreement with Nationwide Children’s Hospital for microdystrophin gene therapy program. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

PBF Energy Inc. (PBF) dropped $0 to close the day at a new closing price of $24.36, a 0% decrease in value from its previous closing price that moved the stock 25.12% above its 52 week low of $19.47. A total of 2.06M shares exchanged hands during the day compared with its three month average trading volume of 2.49M. The stock, which fluctuated between $24.28 and $24.75 during the day, currently situated -30.07% below its 52 week high. The stock is up by 0.7% in the past one month and up by 11.39% over the past three months. With a one year target estimate of $28.71 and RSI of 47.9, the stock still has upside potential, making it a hold for now.

PBF Energy Inc., together with its subsidiaries, engages in the refining and supply of petroleum products. It produces gasoline, ultra-low-sulfur diesel, heating oil, diesel fuel, jet fuel, lubricants, petrochemicals, and asphalt, as well as unbranded transportation fuels, petrochemical feedstocks, blending components, and other petroleum products. The company sells its products in Northeast and Midwest of the United States, as well as in other regions of the United States and Canada. PBF Energy Inc. was founded in 2008 and is based in Parsippany, New Jersey.

 

Equities Trend Analysis: Kohl’s Corporation (KSS), Murphy Oil Corporation (MUR), Sarepta Therapeutics, Inc. (SRPT)

Kohl’s Corporation (KSS) retreated with the stock falling -0.18% or $-0.07 to close at $39.15 on light trading volume of 3.69M compared its three months average trading volume of 4.86M. The Menomonee Falls Wisconsin 53051 based company operating under the Department Stores industry has been trending down for the last 52 weeks, with the shares price now -3.95% down for the period and down by -20.72% so far this year. With price target of $46.19 and a 19.56% rebound from 52-week low, Kohl’s Corporation has plenty of upside potential, making it a hold with a view buy.

Kohl’s Corporation operates department stores in the United States. It offers private label, exclusive, and national brand apparel, footwear, accessories, beauty, and home products to children, men, and women customers. The company also sells its products online through Website Kohls.com. As of January 30, 2016, it operated 1,164 department stores in 49 states. Kohl’s Corporation was founded in 1962 and is headquartered in Menomonee Falls, Wisconsin.

Murphy Oil Corporation (MUR) had a active trading with around 3.69M shares changing hands compared to its three month average trading volume of 2.87M. The stock traded between $27.57 and $28.73 before closing at the price of $27.95 with -3.92% change on the day. The El Dorado Arkansas 71730 based company is currently trading 89.1% above its 52 week low of $15.23 and -23.16% below its 52 week high of $37.48. Both the RSI indicator and target price of  and $32.56 respectively, lead us to believe that it could rise over the coming weeks.

Murphy Oil Corporation operates as an oil and gas exploration and production company worldwide. It explores for and produces crude oil, natural gas, and natural gas liquids. The company was formerly known as Murphy Corporation and changed its name to Murphy Oil Corporation in 1964. Murphy Oil Corporation was founded in 1950 and is headquartered in El Dorado, Arkansas.

Sarepta Therapeutics, Inc. (SRPT) saw its value increase by 0.34% as the stock gained $0.1 to finish the day at a closing price of $29.17. The stock was higher in trading and has fluctuated between $8-$63.73 per share for the past year. The shares, which traded within a range of $28.74 to $30.9 during the day, are down by -25.61% in the past three months and up by 10.41% over the past six months. It is currently trading -9.97% below its 20 day moving average and -8.66% below its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $62.89 a share over the next twelve months. The current relative strength index (RSI) reading is 41.92.The technical indicator lead us to believe there will be no major movement any time soon, hold.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. The company’s lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development for the treatment of individuals with Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease caused by the absence of dystrophin. It is also developing exon-skipping drugs for the treatment of DMD; and therapeutic candidates for the treatment of infectious diseases, such as influenza, Marburg, and Ebola. The company has a strategic alliance with Charley’s Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies; a license agreement with the University of Western Australia for the use of antisense sequences in the treatment of DMD; and a research collaboration agreement with Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD. It also has a research and option agreement with Nationwide Children’s Hospital for microdystrophin gene therapy program. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

 

Worth Watching Stocks: Sarepta Therapeutics, Inc. (SRPT), Tidewater Inc. (TDW), Legg Mason, Inc. (LM)

Sarepta Therapeutics, Inc. (SRPT) saw its value decrease by -6.03% as the stock dropped $-1.86 to finish the day at a closing price of $28.97. The stock was lighter in trading and has fluctuated between $8-$63.73 per share for the past year. The shares, which traded within a range of $28.75 to $30.62 during the day, are down by -29.01% in the past three months and up by 14.6% over the past six months. It is currently trading -9.94% below its 20 day moving average and -12.07% below its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $62.94 a share over the next twelve months. The current relative strength index (RSI) reading is 38.87.The technical indicator lead us to believe there will be no major movement any time soon, hold.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. The company’s lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development for the treatment of individuals with Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease caused by the absence of dystrophin. It is also developing exon-skipping drugs for the treatment of DMD; and therapeutic candidates for the treatment of infectious diseases, such as influenza, Marburg, and Ebola. The company has a strategic alliance with Charley’s Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies; a license agreement with the University of Western Australia for the use of antisense sequences in the treatment of DMD; and a research collaboration agreement with Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD. It also has a research and option agreement with Nationwide Children’s Hospital for microdystrophin gene therapy program. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

Tidewater Inc. (TDW) shares were down in last trading by -8.54% to $2.25. It experienced lighter than average volume on day. The stock increased in value by almost 6.64% over the past week and fell -32.63% in the past month. It is currently trading -25.43% below its 50 day moving average and -44.22% below its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -80.57% decrease in value from its one year high of $11.58. The RSI indicator value of 41.12, lead us to believe that it is a hold for now.

Tidewater Inc. provides offshore service vessels and marine support services to the offshore energy industry through the operation of a fleet of marine service vessels worldwide. The company operates through Americas, Asia/Pacific, Middle East/North Africa, and Sub-Saharan Africa/Europe segments. It provides services in support of offshore exploration, field development, and production, including towing of and anchor handling for mobile offshore drilling units; transporting supplies and personnel necessary to sustain drilling, workover, and production activities; offshore construction, remotely operated vehicle (ROV) operations, and seismic and subsea support; and various specialized services, such as pipe and cable laying. The company operates and charters deepwater vessels, including platform supply vessels, and anchor handling towing supply vessels that are used in transporting supplies and equipment from shore bases to deepwater and intermediate water depth offshore drilling rigs and production platforms; towing-supply vessels for use in intermediate and shallow waters; and crew boats and utility vessels for use in transporting personnel and supplies from shore bases to offshore drilling rigs, platforms, and other installations. It also operates offshore tugs used for towing floating drilling rigs and barges; and assisting in the docking of tankers, as well as in pipe laying, cable laying, and construction barges. The company serves international oil and natural gas exploration, field development, and production companies; select independent exploration and production companies; foreign government-owned or government-controlled organizations and other companies; drilling contractors; and other companies, including offshore construction companies, diving companies, and well stimulation companies. As of March 31, 2016, it owned or chartered 269 vessels and 8 ROVs. Tidewater Inc. was founded in 1956 and is headquartered in New Orleans, Louisiana.

Legg Mason, Inc. (LM) traded within a range of $30.81 to $32.11 after opening the day at $31.37. The company has seen its stock increase in value by 7.29% so far this year. The stock was up close to 2.3% on active volume in last trading session and closed at $32.09 per share. After the recent gain, the stock is currently holding -8.66% below its 52 week high of $35.83 and 32.07% above its 12-month low of $24.93. The shares are up by over 4.51% in the last three months, and the RSI indicator value of 52.66 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Legg Mason, Inc. is a publicly owned asset management holding company. Through its subsidiaries, the firm provides investment management and related services to company-sponsored mutual funds and other investment vehicles including pension funds, foundations, endowments, sovereign wealth funds, insurance companies, private banks, family offices, individuals, as well as to global, institutional, and retail clients. It launches and manages equity, fixed income, and multi-asset customized portfolios through its subsidiaries. The firm also launches and manages mutual funds and exchange traded funds for its clients through its subsidiaries. It invests in private and public equity, fixed income, and multi asset markets across the globe through its subsidiaries. Through its subsidiaries, the firm also invests in alternative markets. It also employs a combination of fundamental and quantitative research to make its investments through its subsidiaries. Legg Mason, Inc. was founded in 1899 and is based in Baltimore, Maryland.

 

Stocks Alert: Sarepta Therapeutics, Inc. (SRPT), Capstead Mortgage Corporation (CMO), Berry Plastics Group, Inc. (BERY)

Sarepta Therapeutics, Inc. (SRPT) retreated with the stock falling -0.66% or $-0.2 to close at $30.05 on light trading volume of 1.27M compared its three months average trading volume of 2.55M. The Cambridge Massachusetts 02142 based company operating under the Biotechnology industry has been trending up for the last 52 weeks, with the shares price now 151.89% up for the period and up by 9.55% so far this year. With price target of $62.94 and a 275.62% rebound from 52-week low, Sarepta Therapeutics, Inc. has plenty of upside potential, making it a hold with a view buy.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. The company’s lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development for the treatment of individuals with Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease caused by the absence of dystrophin. It is also developing exon-skipping drugs for the treatment of DMD; and therapeutic candidates for the treatment of infectious diseases, such as influenza, Marburg, and Ebola. The company has a strategic alliance with Charley’s Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies; a license agreement with the University of Western Australia for the use of antisense sequences in the treatment of DMD; and a research collaboration agreement with Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD. It also has a research and option agreement with Nationwide Children’s Hospital for microdystrophin gene therapy program. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

Capstead Mortgage Corporation (CMO) dropped $-0.01 to close the day at a new closing price of $10.87, a -0.09% decrease in value from its previous closing price that moved the stock 49.23% above its 52 week low of $8.87. A total of 1.27M shares exchanged hands during the day compared with its three month average trading volume of 747.67K. The stock, which fluctuated between $10.66 and $10.96 during the day, currently situated -0.82% below its 52 week high. The stock is up by 6.15% in the past one month and up by 16.99% over the past three months. With a one year target estimate of $9.33 and RSI of 63.61, the stock still has upside potential, making it a hold for now.

Capstead Mortgage Corporation operates as real estate investment trust (REIT) in the United States. It invests in a portfolio of residential mortgage pass-through securities primarily consisting of short-duration adjustable-rate mortgage securities issued and guaranteed by government-sponsored enterprises, or by an agency of the federal government. The company qualifies as a REIT for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 1985 and is headquartered in Dallas, Texas.

Berry Plastics Group, Inc. (BERY) shares were down in last trading by -0.92% to $51.56. It experienced lighter than average volume on day. The stock increased in value by almost 1.6% over the past week and grew 2.53% in the past month. It is currently trading 4.44% above its 50 day moving average and 19.66% above its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -2.66% decrease in value from its one year high of $52.97. The RSI indicator value of 59.55, lead us to believe that it is a hold for now.

Berry Plastics Group, Inc. manufactures and distributes plastic consumer packaging and engineered materials in the United States, Canada, Mexico, Belgium, France, Spain, the United Kingdom, Italy, Germany, Australia, Brazil, Argentina, Colombia, Malaysia, India, China, and the Netherlands. The company operates through three segments: Health, Hygiene & Specialties; Consumer Packaging; and Engineered Materials. It offers containers; foodservice products, such as thermoformed polypropylene and injection-molded plastic drink cups; closures and over caps comprising continuous-thread and child-resistant closures, as well as aerosol over caps; bottle and prescription containers; and extruded and laminate tubes. The company also provides engineered materials, including corrosion protection products; and cloth and foil, splicing and laminating, flame-retardant, vinyl-coated and carton sealing, electrical, double-faced cloth, masking, mounting, OEM, and medical and specialty tapes. The company’s engineered materials also consists of drop cloths and retail trash bags; polyvinyl chloride films and boxed products; trash-can liners and food bags; and stretch and shrink films. In addition, it offers flexible packaging products, such as personal care films; food and consumer films, as well as barrier films; and converter films, including coated and laminated products, as well as a range of products for the food, healthcare, and personal care markets. The company sells its products through direct sales force and distributors. Berry Plastics Group, Inc. was founded in 1967 and is headquartered in Evansville, Indiana.

 

3 Stocks to Watch For: Williams Partners L.P. (WPZ), TTM Technologies, Inc. (TTMI), Sarepta Therapeutics, Inc. (SRPT)

Williams Partners L.P. (WPZ) saw its value increase by 1.56% as the stock gained $0.63 to finish the day at a closing price of $41.11. The stock was higher in trading and has fluctuated between $12.69-$41.4 per share for the past year. The shares, which traded within a range of $40.47 to $41.4 during the day, are up by 16.39% in the past three months and up by 17.06% over the past six months. It is currently trading 8.47% above its 20 day moving average and 13.37% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $55 a share over the next twelve months. The current relative strength index (RSI) reading is 76.25.The technical indicator do not lead us to believe the stock will see more gains any time soon.

Williams Partners L.P. operates as an energy infrastructure company. It operates through Central, Northeast G&P, Atlantic-Gulf, West, and NGL & Petchem Services segments. The Central segment provides gathering, treating, and compression services to producers in the Barnett shale region of north-central Texas, the Eagle Ford shale region of south Texas, the Haynesville shale region of northwest Louisiana, and the Mid-Continent region. The Northeast G&P segment engages in the natural gas gathering and processing, and NGL fractionation businesses in the Marcellus and Utica shale regions in Pennsylvania, West Virginia, New York, and Ohio. The Atlantic-Gulf segment engages in the interstate natural gas pipeline; and natural gas gathering and processing, and crude oil production handling and transportation activities in the Gulf Coast region. The West segment engages in the natural gas gathering, processing, and treating operations in New Mexico, Colorado, and Wyoming, as well as operates the interstate natural gas pipeline and the Northwest Pipeline. The NGL & Petchem Services segment engages in the operation of an olefins production facility in Geismar, Louisiana; a refinery grade propylene splitter, and various petrochemical and feedstock pipelines in the Gulf Coast region; an oil sands offgas processing plant near Fort McMurray, Alberta; an (natural gas liquids) NGL/olefin fractionation facility; and storage facilities and an NGL fractionator near Conway, Kansas, as well as NGL and natural gas marketing business. WPZ GP LLC serves as the general partner of the company. The company was founded in 2005 and is based in Tulsa, Oklahoma. Williams Partners L.P. operates as a subsidiary of Williams Companies, Inc.

TTM Technologies, Inc. (TTMI) shares were down in last trading by -0.07% to $14.64. It experienced higher than average volume on day. The stock increased in value by almost 7.65% over the past week and grew 7.41% in the past month. It is currently trading 6.88% above its 50 day moving average and 44.09% above its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -2.4% decrease in value from its one year high of $15. The RSI indicator value of 63.79, lead us to believe that it is a hold for now.

TTM Technologies, Inc., together with its subsidiaries, manufactures printed circuit boards (PCBs) worldwide. It provides a range of PCBs and electro-mechanical solutions, including high density interconnect PCBs, conventional PCBs, flexible PCBs, rigid-flex PCBs, custom assemblies and system integration, and IC substrates. It also produces test specialized circuits used in radio-frequency or microwave emission and collection applications; printed circuits with heavy copper cores, and embedded and press-fit coins; PCBs with electrically passive heat sinks; and PCBs with electrically active thermal cores. In addition, the company offers various services, including manufacturability, PCB layout design, simulation and testing, and quick turnaround services. The company’s customers include original equipment manufacturers and electronic manufacturing services companies that primarily serve the networking/communications, cellular phone, computing, aerospace and defense, and medical/industrial/instrumentation end markets of the electronics industry. TTM Technologies, Inc. was founded in 1978 and is headquartered in Costa Mesa, California.

Sarepta Therapeutics, Inc. (SRPT) opening the day at $37.5. The company has seen its stock increase in value by 31.72% so far this year. The stock was down close to -4.49% on light volume in last trading session and closed at $36.13 per share. After the recent fall, the stock is currently holding -43.31% below its 52 week high of $63.73 and 351.63% above its 12-month low of $8. The shares are down by over -30.89% in the last three months, and the RSI indicator value of 59.06 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. The company’s lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development for the treatment of individuals with Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease caused by the absence of dystrophin. It is also developing exon-skipping drugs for the treatment of DMD; and therapeutic candidates for the treatment of infectious diseases, such as influenza, Marburg, and Ebola. The company has a strategic alliance with Charley’s Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies; a license agreement with the University of Western Australia for the use of antisense sequences in the treatment of DMD; and a research collaboration agreement with Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD. It also has a research and option agreement with Nationwide Children’s Hospital for microdystrophin gene therapy program. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

 

Stocks Buzz: Sarepta Therapeutics, Inc. (SRPT), Amgen Inc. (AMGN), New York REIT, Inc. (NYRT)

Sarepta Therapeutics, Inc. (SRPT) continued its upward trend with the stock climbing 2.99% or $1.1 to close the day at $37.83 on active trading volume of 2.63M shares, compared to its three month average trading volume of 2.58M. The Cambridge Massachusetts 02142 based company has been outperforming the biotechnology group over the past 52 weeks, with the stock gaining 19.6%, compared to the industry which has advanced 3.17% over the same period. With RSI of 64.59, the stock should still continue to rise and get closer to its one year target estimate of $62.94, making it a hold for now.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. The company’s lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development for the treatment of individuals with Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease caused by the absence of dystrophin. It is also developing exon-skipping drugs for the treatment of DMD; and therapeutic candidates for the treatment of infectious diseases, such as influenza, Marburg, and Ebola. The company has a strategic alliance with Charley’s Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies; a license agreement with the University of Western Australia for the use of antisense sequences in the treatment of DMD; and a research collaboration agreement with Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD. It also has a research and option agreement with Nationwide Children’s Hospital for microdystrophin gene therapy program. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

Amgen Inc. (AMGN) grew with the stock adding 0.49% or $0.76 to close at $156.12 on light trading volume of 2.62M compared its three months average trading volume of 4.15M. The Thousand Oaks California 91320 based company operating under the Biotechnology industry has been trending up for the last 52 weeks, with the shares price now 4.62% up for the period and up by 6.78% so far this year. With price target of $181.73 and a 17.61% rebound from 52-week low, Amgen Inc. has plenty of upside potential, making it a hold with a view buy.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company’s products include Neulasta, a pegylated protein for the treatment of cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis. Its products also comprise EPOGEN to treat a lower-than-normal number of red blood cells caused by chronic kidney disease (CKD) in patients on dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; Repatha for the treatment of cholesterol; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. The company’s other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with Xencor, Inc; UCB; Novartis AG; Bayer HealthCare Pharmaceuticals Inc; Advaxis, Inc.; Dr. Reddy’s Laboratories Ltd.; Biocartis Group NV; and Nuevolution AB. The company also has a strategic collaboration with Immatics Biotechnologies GmbH. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

New York REIT, Inc. (NYRT) continued its upward trend with the stock climbing 0.3% or $0.03 to close the day at $9.87 on lower than average trading volume of 2.62M shares, compared to its three month average trading volume of 2.66M. The New York New York 10022 based company has been outperforming the reit – office companies by 6.5319% for last three months and its recent gains have offset losses to -2.47% YTD, versus the reit – office industry which is up 1.22% for the same period. The RSI of 51.74 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

New York REIT, Inc. focuses on acquiring commercial real estate, as well as acquiring properties or making other real estate investments that relate to office, retail, multi-family residential, industrial, and hotel property types located primarily in New York City. It intends to qualify as a real estate investment trust for the U.S. federal income tax purposes. The company was formerly known as American Realty Capital New York Recovery REIT, Inc. New York REIT, Inc. was founded in October 2009 and is based in New York, New York.

 

Worth Watching Stocks: Netflix, Inc. (NFLX), CenturyLink, Inc. (CTL), Sarepta Therapeutics, Inc. (SRPT)

Netflix, Inc. (NFLX) saw its value increase by 0.47% as the stock gained $0.61 to finish the day at a closing price of $130.5. The stock was lighter in trading and has fluctuated between $79.95-$133.88 per share for the past year. The shares are up by 29.73% in the past three months and up by 35.33% over the past six months. It is currently trading 3.1% above its 20 day moving average and 6.58% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $124.35 a share over the next twelve months. The current relative strength index (RSI) reading is 64.43.The technical indicator lead us to believe there will be no major movement any time soon, hold.

Netflix, Inc., an Internet television network, engages in the Internet delivery of television (TV) shows and movies on various Internet-connected screens. The company operates in three segments: Domestic streaming, International streaming and Domestic DVD. It offer members with the ability to receive TV shows and movies streaming content, including original series, documentaries, and feature films through a host of Internet-connected screens, such as TVs, digital video players, TV set-top boxes, and mobile devices. The company also provides DVDs-by-mail membership services. As of October 17, 2016, it served approximately 86 million streaming members in 190 countries. Netflix, Inc. was founded in 1997 and is headquartered in Los Gatos, California.

CenturyLink, Inc. (CTL) shares were up in last trading by 0.16% to $25.24. It experienced lighter than average volume on day. The stock decreased in value by almost -0.94% over the past week and grew 4.64% in the past month. It is currently trading 3.98% above its 50 day moving average and -6.42% below its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -22.89% decrease in value from its one year high of $33.45. The RSI indicator value of 63.24, lead us to believe that it is a hold for now.

CenturyLink, Inc. provides various communications services to residential, business, wholesale, and governmental customers in the United States. It operates through two segments, Business and Consumer. The company offers high-speed Internet services, which allow customers to connect to the Internet through their existing telephone lines or fiber-optic cables; multi-protocol label switching, a data networking technology to support real-time voice and video; and private line services for the transmission of data between sites. It also provides Ethernet services, including point-to-point and multi-point equipment configurations that facilitate data transmissions across metropolitan areas and wide area networks (WAN); colocation services that enable its customers to install their own information technology (IT) equipment; and managed hosting services comprising cloud and traditional computing, application management, back-up, storage, and other services. In addition, the company offers video entertainment services and satellite digital television; Voice over Internet Protocol, a real-time, two-way voice communication service; and managed services that consist of network, hosting, cloud, and IT services. Further, it provides local calling, long-distance voice, integrated services digital network, WAN, and switched access services; and data integration, which includes the sale of telecommunications equipment and providing network management, installation, and maintenance of data equipment, and the building of proprietary fiber-optic broadband networks. Additionally, the company leases and subleases space in its office buildings, warehouses, and other properties. As of December 31, 2015, it served approximately 6 million high-speed Internet subscribers and 285 thousand television subscribers; and operated 59 data centers in North America, Europe, and Asia. CenturyLink, Inc. was founded in 1968 and is headquartered in Monroe, Louisiana.

Sarepta Therapeutics, Inc. (SRPT) opening the day at $38.24. The company has seen its stock increase in value by 29.6% so far this year. The stock was down close to -6.18% on active volume in last trading session and closed at $35.55 per share. After the recent fall, the stock is currently holding -44.22% below its 52 week high of $63.73 and 344.37% above its 12-month low of $8. The shares are down by over -33.95% in the last three months, and the RSI indicator value of 59.51 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. The company’s lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development for the treatment of individuals with Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease caused by the absence of dystrophin. It is also developing exon-skipping drugs for the treatment of DMD; and therapeutic candidates for the treatment of infectious diseases, such as influenza, Marburg, and Ebola. The company has a strategic alliance with Charley’s Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies; a license agreement with the University of Western Australia for the use of antisense sequences in the treatment of DMD; and a research collaboration agreement with Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

 

Investor’s Alert: Merck & Co., Inc. (MRK), Sarepta Therapeutics, Inc. (SRPT), Kinder Morgan, Inc. (KMI)

Merck & Co., Inc. (MRK) failed to extend gains with the stock declining -1.93% or $-1.18 to close the day at $59.92 on higher than average trading volume of 15.15M shares, compared to its three month average trading volume of 10.8M. The Kenilworth New Jersey 07033 based company has been underperforming the drug manufacturers – major companies by -5.4901% for last three months and its recent losses have trimmed gains to 1.78% YTD, versus the drug manufacturers – major industry which is up 2.24% for the same period. The RSI of 44.33 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments for otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company has collaboration agreements with Adaptimmune Therapeutics plc and Agenus; and a research agreement with Proteros Biostructures to develop molecule compounds for various cancer treatments. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Sarepta Therapeutics, Inc. (SRPT) had a light trading with around 14.82M shares changing hands compared to its three month average trading volume of 2.39M. The stock traded at the price of $37.89 with 21.21% change on the day. The Cambridge Massachusetts 02142 based company is currently trading 373.62% above its 52 week low of $8 and -40.55% below its 52 week high of $63.73. Both the RSI indicator and target price of 67.47 and $64.33 respectively, lead us to believe that it should be put on hold over the coming weeks.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. The company’s lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development for the treatment of individuals with Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease caused by the absence of dystrophin. It is also developing exon-skipping drugs for the treatment of DMD; and therapeutic candidates for the treatment of infectious diseases, such as influenza, Marburg, and Ebola. The company has a strategic alliance with Charley’s Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies; a license agreement with the University of Western Australia for the use of antisense sequences in the treatment of DMD; and a research collaboration agreement with Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

Kinder Morgan, Inc. (KMI) traded within a range of $21.49 to $21.8 after opening the day at $21.74. The company has seen its stock increase in value by 4.15% so far this year. The stock was down close to -0.32% on active volume in last trading session and closed at $21.57 per share. After the recent fall, the stock is currently holding -7.11% below its 52 week high of $23.36 and 98.03% above its 12-month low of $11.2. The shares are up by over 1.3% in the last three months, and the RSI indicator value of 54.43 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Kinder Morgan, Inc. operates as an energy infrastructure company in North America. It operates through Natural Gas Pipelines, CO2, Terminals, Products Pipelines, Kinder Morgan Canada, and Other segments. The Natural Gas Pipelines segment owns and operates interstate and intrastate natural gas pipeline and storage systems; natural gas and crude oil gathering systems, and natural gas processing and treating facilities; natural gas liquids fractionation facilities and transportation systems; and liquefied natural gas facilities. The CO2 segment produces, transports, and markets CO2 for use in enhanced oil recovery projects; and owns interests in oil-producing fields, gas processing plants, and crude oil pipelines in the Permian Basin region of West Texas. The Terminals segment owns and operates liquids and bulk terminals that transload and store refined petroleum products, crude oil, and condensate, as well as bulk products, including coal, petroleum coke, cement, alumina, salt, and other bulk chemicals; and owns and operates tankers. The Products Pipelines segment owns and operates refined petroleum products, and crude oil and condensate pipelines; and associated product terminals and petroleum pipeline transmix facilities. The Kinder Morgan Canada segment owns and operates Trans Mountain pipeline system that transports crude oil and refined petroleum products from Edmonton, Alberta, and Canada to marketing terminals and refineries in British Columbia, Canada, and Washington; and jet fuel aviation turbine fuel pipeline that serves the Vancouver (Canada) International Airport. The Other segment includes various physical natural gas contracts with power plants. Kinder Morgan, Inc. owns interests in or operates approximately 84,000 miles of pipelines and 180 terminals. The company was formerly known as Kinder Morgan Holdco LLC and changed its name to Kinder Morgan, Inc. in February 2011. Kinder Morgan, Inc. was founded in 1936 and is headquartered in Houston, Texas.